Keros Therapeutics Inc (KROS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $202.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
Keros Therapeutics Inc (KROS) Financials: Revenue, Profit and Cash Flow
Keros Therapeutics reported revenue of $244.06M for the fiscal year ended Dec 31, 2025, up 6775.0% from the year before. That year, net income was $87.01M with a net margin of 35.7%, operating cash flow was $107.50M and free cash flow was $105.95M. The quarter ended Sep 30, 2026 had revenue of $40.01M and net income of $14.15M.
Revenue and Margins
The operating margin was 27.7% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $10.00M, a compound annual rate of 57.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $244.06M | +6775.0% | 100.0% | 27.7% | 35.7% |
| Dec 2024 | $3.55M | +2251.0% | 100.0% | -5939.0% | -5277.5% |
| Dec 2023 | $151.00K | N/A | 100.0% | -112543.7% | -101319.2% |
| Dec 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | $20.10M | N/A | 100.0% | -280.5% | -292.3% |
| Dec 2020 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2019 | $10.00M | 0.0% | 100.0% | -105.6% | -123.4% |
| Dec 2018 | $10.00M | N/A | -1.1% | -16.9% | -13.4% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $244.06M | $3.55M | $151.00K | $0 | $20.10M | $0 | $10.00M | $10.00M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10.11M |
| Gross profit | $244.06M | $3.55M | $151.00K | $0 | $20.10M | $0 | $10.00M | -$111.00K |
| Research and development | $129.64M | $173.63M | $135.26M | $87.27M | $55.14M | $33.86M | $17.38M | $10.11M |
| Operating income | $67.57M | -$210.83M | -$169.94M | -$114.79M | -$56.37M | -$46.66M | -$10.56M | -$1.69M |
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M | -$58.74M | -$45.36M | -$12.34M | -$1.33M |
| EBITDA | $68.54M | -$207.50M | -$165.38M | -$114.73M | -$55.86M | N/A | N/A | -$774.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.01M | $0 | $367.00K | $385.00K | $14.26M | $18.17M | $211.25M | $3.04M | $388.00K | $37.00K | $83.00K | $143.00K |
| Gross profit | $40.01M | $0 | $367.00K | $385.00K | $14.26M | $18.17M | $211.25M | $3.04M | $388.00K | $37.00K | $83.00K | $143.00K |
| Operating income | $12.82M | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M | $152.04M | -$53.25M | -$58.66M | -$50.44M | -$48.48M | -$46.45M |
| Net income | $14.15M | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | $148.45M | -$46.03M | -$52.96M | -$45.26M | -$43.11M | -$40.24M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.41M by $285.01M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $338.02M | $615.89M | $370.02M | $306.78M | $255.25M | $269.44M | $10.96M | $27.41M |
| Current assets | $315.43M | $588.89M | $347.29M | $285.77M | $251.44M | $267.73M | $8.93M | $25.53M |
| Cash and equivalents | $287.42M | $559.93M | $331.15M | $279.05M | $230.04M | $265.88M | $7.02M | $23.26M |
| Total liabilities | $34.89M | $44.33M | $37.81M | $29.36M | $12.08M | $7.72M | $10.46M | $14.65M |
| Short-term debt | $2.41M | $1.98M | $1.00M | $455.00K | $862.00K | $423.00K | $376.00K | $166.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | $4.96M | $2.39M |
| Shareholder equity | $303.13M | $571.55M | $332.21M | $277.42M | $243.17M | $261.72M | -$19.45M | $12.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $307.37M | $287.60M | $312.29M | $338.02M | $742.78M | $757.16M | $784.56M | $615.89M | $579.27M | $455.02M | $485.82M | $370.02M |
| Total liabilities | $28.27M | $25.28M | $26.66M | $34.89M | $39.20M | $50.43M | $55.69M | $44.33M | $46.44M | $34.11M | $31.87M | $37.81M |
| Cash and equivalents | $259.46M | $257.61M | $281.50M | $287.42M | $693.47M | $690.22M | $720.54M | $559.93M | $530.68M | $405.86M | $442.44M | $331.15M |
| Shareholder equity | $279.10M | $262.32M | $285.63M | $303.13M | $703.58M | $706.73M | $728.87M | $571.55M | $532.84M | $420.92M | $453.95M | $332.21M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow. Share repurchases came to 353.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $107.50M | -$160.87M | -$124.51M | -$70.06M | -$62.15M | -$36.89M | -$16.00M | $7.04M |
| Capital expenditures | $1.56M | $1.93M | $2.46M | $1.24M | $1.02M | $294.00K | $271.00K | $217.00K |
| Free cash flow | $105.95M | -$162.80M | -$126.97M | -$71.30M | -$63.17M | -$37.19M | -$16.27M | $6.83M |
| Share repurchases | $375.00M | $171.00K | $94.00K | $87.00K | N/A | $227.00K | $0 | N/A |
| Investing cash flow | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M | -$294.00K | -$271.00K | -$217.00K |
| Financing cash flow | -$378.47M | $391.82M | $178.96M | $120.31M | $28.55M | $296.04M | $14.00K | $11.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.39M | -$20.42M | -$3.53M | -$27.29M | $3.25M | -$29.62M | $161.17M | -$46.01M | -$30.50M | -$39.80M | -$44.56M | -$25.46M |
| Capital expenditures | $59.00K | $155.00K | $73.00K | $134.00K | $132.00K | $720.00K | $565.00K | $289.00K | $386.00K | $310.00K | $946.00K | $541.00K |
| Free cash flow | $3.33M | -$20.58M | -$3.60M | -$27.43M | $3.12M | -$30.34M | $160.61M | -$46.30M | -$30.89M | -$40.11M | -$45.51M | -$26.00M |
Frequently Asked Questions About KROS
What is Keros Therapeutics' annual revenue?
Keros Therapeutics reported revenue of $244.06M for the fiscal year ended Dec 31, 2025.
How fast is Keros Therapeutics' revenue growing?
Revenue was up 6775.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Keros Therapeutics profitable?
Yes. Keros Therapeutics reported net income of $87.01M for the fiscal year ended Dec 31, 2025, with a net margin of 35.7%.
How much free cash flow does KROS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $107.50M minus capital expenditures of $1.56M produced free cash flow of $105.95M.
How much debt does Keros Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.41M and cash and equivalents of $287.42M.
KROS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors